Drug Trial Radar · NCT07167914
A Study to Assess Safety, Tolerability and Pharmacokinetics of Transdermal SFG-02 in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Sep 9, 2025
Primary completion
Apr 27, 2026
Study completion Apr 27, 2026
Sponsor
- Lead sponsor
- Juro Sciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of a novel transdermal formulation of SFG-02 following single and repeated applications in Japanese and White healthy adult participants.
Conditions
- Health Participants
Interventions
SFG-02Drug
Transdermal Formulation (SFG-02)
PlaceboDrug
Transdermal Formulation (Placebo)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: From the first application to the 14th day after the final application
- Pharmacokinetics (PK): Maximum concentration (Cmax) of SFG-02Time frame: At designated timepoints (up to 7 days after the final application)
- PK: Area under the concentration versus time curve (AUC) of SFG-02Time frame: At designated timepoints (up to 7 days after the final application)
- PK: Time to maximum concentration (Tmax) of SFG-02Time frame: At designated timepoints (up to 7 days after the final application)
- PK: Time to decrease the concentration by half (T1/2) of SFG-02Time frame: At designated timepoints (up to 7 days after the final application)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sumida Hospital
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.